Trump Administration Initiatives Address Drug Prices, Tariffs, and Manufacturing

The Trump administration implemented a series of initiatives aimed at reducing prescription drug costs for U.S. consumers, promoting domestic pharmaceutical manufacturing, and revising tariff policies. These efforts included the launch of the TrumpRx website for discounted medications, "most-favored-nation" pricing agreements, and new tariffs tied to drug price reductions and U.S. production commitments.

While some agreements included specific drug price reductions and expanded access, independent analyses indicated varied impacts on overall drug prices, with some companies raising list prices for certain products.

Concurrently, the Biden-era Inflation Reduction Act introduced Medicare drug price negotiations, leading to separate price adjustments for some medications.

Trump Administration's Drug Pricing Initiatives

The Trump administration introduced several policies and agreements with pharmaceutical companies with the stated objective of lowering prescription drug costs for U.S. consumers. These efforts also aimed to align U.S. drug prices with those in other developed nations and encourage domestic manufacturing.

Key initiatives included:

• The launch of the TrumpRx website.
• "Most-favored-nation" pricing agreements with pharmaceutical manufacturers.
• A new tariff structure for imported pharmaceuticals.

The TrumpRx Platform

The Trump administration announced the launch of TrumpRx.gov, a direct-to-consumer website designed to connect cash-paying patients with drug manufacturers offering discounts. White House press secretary Karoline Leavitt announced the website's debut for 7 p.m. ET on a Thursday, with some reports confirming its launch. However, other sources indicated that a broader version of the TrumpRx website (sometimes referenced as TrumpRx.com) was projected to launch in early to late 2026.

The platform functions as a portal, directing users to drug manufacturers' websites for discounted prescriptions rather than selling drugs directly. It is primarily intended for individuals paying out-of-pocket, including the uninsured or those with high-deductible plans, as it does not accept insurance, and purchases do not count towards deductibles.

Eligibility for some discounts may require customers to declare they are not enrolled in government insurance programs like Medicare or Medicaid and will not seek insurance reimbursement.

Initial offerings included 43 drugs from five companies: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer, with plans to include discounts from an additional 11 companies. Reported discounts varied, such as 33% off Pfizer's Xeljanz and 93% off EMD Serono's Cetrotide.

Examples of proposed savings through TrumpRx included:

• Wegovy at $149 per month, a reduction from $1,349.
• Gonal F (fertility treatment) at an 83% discount.
• Merck's Januvia (Type 2 diabetes) at $100, down from $330.
• Amgen's Repatha (cholesterol) at $239, down from $573.
• Certain injectable obesity medications available at an average of $350 per month, projected to decrease to $245 over 24 months.

Juliette Cubanski of KFF indicated that TrumpRx might not be a comprehensive solution for most Americans, noting that insured patients with affordable co-pays might not find significant advantages. Dr. Ben Rome, a health policy researcher, suggested that the website's benefits would likely be limited to specific groups, such as those whose medications (e.g., fertility treatments, obesity drugs) are not covered by their insurance. He also observed that some drugs on TrumpRx, like Protonix, are available as less expensive generics through other discount platforms, such as GoodRx.

Agreements with Pharmaceutical Companies

The Trump administration secured "most-favored-nation" pricing deals with a total of 14 pharmaceutical manufacturers. Initially, agreements were made with nine companies, followed by deals with Johnson & Johnson, Novo Nordisk, Eli Lilly, and nine additional companies including Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi.

In exchange for specific incentives, participating drugmakers committed to:

• Reducing drug prices for consumers and offering Medicaid access at prices consistent with those in other developed countries.
• Launching new drugs in the U.S. at prices no higher than those in other high-income countries.
• Investing in U.S. manufacturing operations. Johnson & Johnson announced plans to construct two new manufacturing facilities in North Carolina and Pennsylvania as part of its $55 billion U.S. investment plan. Overall, companies committed to investing at least $150 billion in U.S. manufacturing.
• Participating in the TrumpRx website to offer discounted rates for cash-paying customers.

As part of these agreements, pharmaceutical companies received a three-year exemption from potential administration tariffs.

Pharmaceutical Tariffs Policy

The U.S. government issued orders for new tariffs on certain branded pharmaceutical imports, linked to drug price reductions and domestic manufacturing. These measures were partly intended to restore duties lost after a Supreme Court decision in February.

Foreign manufacturers of patented pharmaceutical products could avoid tariffs by agreeing to two conditions:

1. Reduce prescription drug prices.
2. Commit to moving production to the United States.

• A 20% tariff would apply if manufacturers relocated some production to the U.S. but did not commit to cutting prices.
• A 100% duty would be imposed on manufacturers who fulfilled neither condition.

• Tariffs on branded drugs from the European Union, Japan, South Korea, and Switzerland were capped at 15% under existing trade agreements.
• A separate agreement with Britain guaranteed zero tariffs on British-made pharmaceuticals for a minimum of three years, contingent on Britain expanding production in the U.S.

Large pharmaceutical companies were given 120 days to comply with these new regulations before the 100% tariff rates took effect, while smaller producers were allowed 180 days.

Observed Price Changes and Expert Analysis (Early 2026)

In January, a period typically associated with pharmaceutical price adjustments, an analysis by 46brooklyn, a drug price research firm, indicated that 16 major pharmaceutical companies that had signed deals with the Trump administration subsequently increased list prices for some of their drugs.

The analysis found that these companies, along with others, raised the prices of 872 brand-name drugs in the first two weeks of 2026. The median price increase was reported as 4%, affecting medications for conditions such as cancer, heart failure, Type 2 diabetes, and certain COVID vaccines. List prices serve as the initial point for negotiations with insurers and pharmacy benefit managers, influencing coverage and patient out-of-pocket costs.

• Pfizer, which had an agreement with the Trump administration, increased prices on 72 products, including a 15% increase on its COVID vaccine. The company stated its price increases were modest and necessary for investment in new medicines and to cover added expenses, noting that prices paid by insurance companies after discounts and rebates had decreased.
• Merck raised prices on 18 products, such as Isentress for HIV and Belsomra for insomnia, attributing these decisions to reflect a product's clinical value. A company spokesperson confirmed work on "fairer global pricing" but stated the exact terms of its agreement with the administration were "confidential."

A White House spokesperson stated that list prices were not the primary focus, and that specific discounts from the deals applied to state Medicaid programs and cash-paying patients for certain prescriptions.

Dr. Ben Rome suggested that these efforts might not significantly impact prices for most of the companies' products or for general healthcare consumers and insurance plans, also noting that Medicaid already receives such discounts.

In contrast to the price increases, 18 significant price cuts were observed in the first days of 2026. Four of these reductions involved drugs part of the first round of Medicare drug price negotiation, an initiative under the Biden administration's Inflation Reduction Act. These included:

• Novo Nordisk's Fiasp (insulin), which saw a 75% price cut in the commercial market.
• AstraZeneca's Farxiga, Boehringer Ingelheim's Jardiance (both for diabetes and heart failure), and Bristol Myers Squibb's Eliquis (a blood thinner), which experienced price drops ranging from 37% to 44%.

Some observers suggested that the Medicare drug price negotiations were a significant factor in these reductions, while others offered a more cautious view, citing a "confluence of factors."

Biden-Era Medicare Drug Price Negotiations

In a separate development, the federal government announced the results of its latest round of Medicare drug price negotiations, enabled by a provision in the Biden-era Inflation Reduction Act passed in 2022. This legislation ended a two-decade prohibition on Medicare negotiating drug prices.

Lower prices were secured for 15 medications, effective in 2027. Medicare is expected to receive a 71% discount on drugs such as Ozempic, Wegovy, and Rybelsus, which are used for obesity and Type 2 diabetes and had list prices around $1,000 per month. Discounts for other drugs ranged from 38% for Austedo to 85% for Janumet. The Centers for Medicare and Medicaid Services (CMS) estimated that if these newly negotiated prices had been in effect in 2024, the program would have saved approximately $12 billion.

A discrepancy was noted between a Trump administration deal with Novo Nordisk from November 6, which aimed to set Ozempic and Wegovy at $245 per month, and the Medicare negotiations for Ozempic, Wegovy, and Rybelsus, which resulted in prices of $274 per month, effective in 2027. Novo Nordisk stated it anticipated further clarification from CMS regarding pricing and coverage mechanisms and affirmed its commitment to advocating for affordable access to its medications while expressing concerns about the Inflation Reduction Act's impact.

Related Initiatives: Metals Tariffs

Concurrently with the pharmaceutical tariff changes, President Trump also adjusted duties on steel, aluminum, and copper. The duty rate on many derivative products containing these metals was halved to 25%, and duties were eliminated for products with minimal metals content (less than 15% by weight). The existing 50% duty on commodity imports of steel, aluminum, and copper remained but was to be applied to the U.S. sales price rather than the declared import value. Additionally, duties on certain metal-intensive industrial and power-grid equipment were reduced from 50% to 15% through 2027 to support industrial and data-center development.